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The aim of this study was to determine the predictive and prognostic value of epidermal growth factor receptor (EGFR) expression in
rectal cancers treated with preoperative high-dose rate brachytherapy and in mismatch-repair (MMR)-proficient colorectal cancers
(CRCs), respectively. We validate the use of receiver operating characteristic (ROC) curve analysis to select cutoff scores for EGFR
overexpression for the end points studied. Immunohistochemistry (IHC) for EGFR was performed on 82 rectal tumour biopsies and
1197 MMR-proficient CRCs using a tissue microarray. Immunoreactivity was scored as the percentage of positive tumour cells by
three pathologists and the inter-observer reliability was assessed. ROC curve-derived cutoffs were used to analyse the association of
EGFR overexpression, tumour response and several clinicopathological features including survival. The scoring method was found to
be reproducible in rectal cancer biopsies and CRCs. The selected cutoff scores from ROC curve analysis for each clinicopathological
feature were highly consistent among pathologists. EGFR overexpression was associated with response to radiotherapy (P-value
o0.001) and with worse survival time (P-value o0.001). In multivariate analysis, EGFR overexpression was independently associated
with adverse prognosis (P-value o0.001). Epidermal growth factor receptor is a predictive marker of response to preoperative
radiotherapy and an independent adverse prognostic factor CRC.
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Epidermal growth factor receptor (EGFR) is a 170-kDa transmem-
brane glycoprotein/cell surface receptor composed of an extra-
cellular ligand-binding domain, a transmembrane lipophilic
segment and an intracellular tyrosine kinase (Grant et al, 2002).
Epidermal growth factor receptor belongs to the ErbB tyrosine
kinase receptor family, which includes four proteins encoded by
the c-erb B proto-oncogene, namely ErbB1 (EGFR), ErbB2 (HER2/
neu), ErbB3 (HER3) and ErbB4 (HER4) (Yarden and Sliwkowski,
2001; Baselga, 2002). Ligand binding produces dimerisation of the
receptor and activation of intrinsic protein tyrosine kinase activity
leading to the transduction of signalling pathways involved in
proliferation, cell division and differentiation (Herbst, 2004). The
MAP kinase and AKT signalling pathways have been found to
mediate intracellular EGFR signalling (Herbst, 2004). The biologic
responses to MAP kinase induction result in increased expression
of proteins governing cell-cycle regulation. AKT, an anti-apoptotic
kinase, is implicated in cell survival and promotion of angiogenesis
and has also been linked to activation of matrix metalloproteinase
protein facilitating tumour growth and promotion (Kainulainen
et al, 2000; Thant et al, 2000).
Expression of EGFR is linked to poor survival in a variety of
malignancies (Neal et al, 1990; Tateishi et al, 1990; Nicholson et al,
1991; Chua et al, 1996; Jonjic et al, 1997; Gamboa-Dominguez et al,
2004). In colorectal cancer (CRC), it is well documented that
EGFR expression may be associated with an advanced disease stage
(Gross et al, 1991; Radinsky, 1995; Radinsky et al, 1995; Prewett
et al, 2002). However, these results remain controversial because
an association between EGFR expression and Dukes stage or length
of survival in CRC has not been detected in other studies (Yasui
et al, 1988; Moorghen et al, 1990; Koenders et al, 1992; Saeki et al,
1995; McKay et al, 2002).
Among the standard techniques such as protein expression,
RNA transcript and DNA assays used to detect EGFR expression
in tumours, immunohistochemistry (IHC) is the most commonly
used in CRC (Italiano, 2006). EGFR expression had been reported
in 25–82% of CRCs (Wan et al, 1988; Radinsky et al, 1995;
Goldstein and Armin, 2001; Yarden and Sliwkowski, 2001; McKay
et al, 2002; Cunningham et al, 2004; Spano et al, 2005a).
It has been recognised that the wide range of methods for
interpreting EGFR expression as determined by IHC considerably
hinders a meta-analysis of the predictive or prognostic value of the
protein in CRC (Italiano, 2006). Despite its subjective nature,
staining intensity has become an integral component of many
EGFR scoring systems (Goldstein and Armin, 2001; Resnick et al,
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s2004; Italiano et al, 2005; Spano et al, 2005b). It has recently been
shown, however, that the degree of staining intensity may be
affected by varying fixation methods and laboratory procedures
and is reduced dramatically with increased storage time of the
tissue samples (Atkins et al, 2004; Italiano et al, 2006). Scoring
methods for EGFR include those evaluating only the degree of
staining intensity (Resnick et al, 2004), those for which positive or
negative expression of EGFR are based on a predetermined and
often arbitrarily set cutoff score (Goldstein and Armin, 2001;
Umemura et al, 2004; Azria et al, 2005; Italiano et al, 2005; Bibeau
et al, 2006) and those with composite systems incorporating both
the extent of positivity and staining intensity (Spano et al, 2005b).
Rarely is the choice of scoring method, in particular the selection
of cutoff scores for positivity, addressed and many remain
unvalidated.
The aim of this study was to determine the predictive value of
EGFR in rectal cancer treated with a novel preoperative radio-
therapy protocol, namely high-dose rate endorectal brachytherapy
(HDREB) and its prognostic value in 1197 mismatch-repair
(MMR)-proficient CRCs using the tissue microarray (TMA)
technique. In pursuing this aim, we propose and validate the
application of receiver operating characteristic (ROC) curve
analysis to the selection of cutoff scores for EGFR overexpression
for the end points under investigation.
MATERIALS AND METHODS
Study Group 1
This study was approved by the Institutional Review Board and
informed written consent was obtained from 82 patients with rectal
adenocarcinoma undergoing preoperative HDREB (Vuong et al,
2002; Vuong et al, 2005). Clinical staging according to the
International Union against Cancer Classification was carried
out by both endorectal ultrasonography and MRI. In cases of
discrepancy, the higher T stage was assigned. Patients with
abdominal nodal disease were excluded from the study, as were
patients with distant metastases. Radiation was delivered pre-
operatively with an eight-channel endorectal catheter using a high-
dose rate remote after-loading system. A daily fraction of 6.5Gy
was administered over 4 consecutive days to a total of 26Gy.
Treatment was planned using a CT simulator to obtain optimal
conformal dosimetry. The dose was prescribed to a clinical target
volume that included the gross tumour volume and any intra-
mesorectal deposits visible at MRI. Patients underwent cancer-
directed surgery 4–8 weeks following radiotherapy regardless of
tumour response.
Tumours were considered completely responsive to preoperative
HDREB when no histologic evidence of residual carcinoma could
be pathologically determined from postoperative surgical resec-
tions (ypT0). Partial response was characterised by the presence
of microfoci or foci of residual carcinoma measuring 0.3–0.9cm
in diameter, whereas no response was defined by large areas of
residual carcinoma that could be identified macroscopically and
ranged in size from 2 to 6cm following irradiation.
Study Group 2
A TMA of 1420 unselected, nonconsecutive CRCs was constructed
(Sauter et al, 2003). Briefly, formalin-fixed, paraffin-embedded
tissue blocks of CRC resections were obtained. One tissue cylinder
with a diameter of 0.6mm was punched from morphologically
representative tissue areas of each donor tissue block and brought
into one recipient paraffin block (3 2.5cm) using a homemade
semiautomated tissue arrayer.
The clinicopathological data for 1420 patients included T stage
(T1, T2, T3 and T4), N stage (N0, N1 and N2), tumour grade (G1,
G2 and G3), vascular invasion (presence or absence) and 10-year
survival. The distribution of these features has been described
previously (Lugli et al, 2006b).
IHC
The 1420 CRCs were dewaxed and rehydrated in dH2O.
Endogenous peroxidase activity was blocked using 0.5% H2O2.
The sections were incubated with 10% normal goat serum (Dako
Cytomation, Carpinteria, CA, USA) for 20min. To determine MMR
status, the 1420 CRCs were incubated with primary antibody for
MLH1 (MLH1 clone MLH-1, BD Biosciences Pharmingen, San Jose,
CA, USA), MSH2 (clone MSH-2, BD Biosciences Pharmingen, San
Jose, CA, USA), and MSH6 (clone 44, Transduction Laboratories,
San Diego, CA, USA) for 2h at room temperature. Subsequently,
sections were incubated with HRP-conjugated secondary antibody
(K4005, EnVisionþ System-HRP (AEC); DakoCytomation,
Carpinteria, CA, USA) for 30min at room temperature. For
visualisation of the antigen, the sections were immersed in 3-
amino-9-ethylcarbazoleþsubstrate-chromogen (DakoCytomation)
for 30min, and counterstained with Gill’s haematoxylin.
IHC for EGFR (clone 3C6, 3mgml
 1, Ventana Medical Systems,
Tucson, USA) was performed on the 82 pretreatment rectal tumour
biopsies as well as on all 1420 CRCs using an autostainer according
to the manufacturer’s recommendations. Positive controls con-
sisted of normal oral mucosa. Negative controls were treated
identically with the primary antibody omitted.
Evaluation of IHC
EGFR immunoreactivity was evaluated as either membranous or
cytoplasmic in a semiquantitative manner using the proportion of
EGFR-positive tumour cells over the total number of tumour cells
ranging from 0 to 100%. Scores were based on 5% intervals (0, 5,
10%, etc). The rectal tumour biopsies were evaluated by three
experienced pathologists (AL, JJ, SH) as were the TMA CRCs (AL,
JJ, DH). For the 1420 CRCs, MLH1, MSH2 and MSH6 were scored
as negative (0% staining) or positive (40% staining). Staining
intensity was not evaluated.
MMR status
The 1420 CRCs were stratified according to DNA MMR status and
consisted of 1197 MMR-proficient tumours expressing MLH1,
MSH2 and MSH6, 141 MLH1-negative tumours and 82 presumed
HNPCC cases demonstrating loss of MSH2 and/or MSH6 at any
age, or loss of MLH1 at o55 years (Hampel et al, 2005). Only
MMR-proficient tumours were included in this study to ensure a
uniform population (N¼1197, 84.4%).
Randomisation of MMR-proficient CRCs
The 1197 MMR-proficient CRCs were randomly assigned into two
groups, Study Group 2A (N¼599) and Study Group 2B (N¼598).
Study Group 2A was used to determine the most relevant cutoff
scores above which a tumour should be considered to overexpress
EGFR for each clinicopathological feature. The associations of
EGFR expression at the proposed cutoff scores with T stage, N
stage, tumour grade, vascular invasion and survival were
investigated on Study Group 2B.
Statistical analysis
Inter-observer reliability of the scoring method The reproduci-
bility of the semiquantitative scoring method in both rectal tumour
biopsies and TMA CRC punches was assessed among three
pathologists and analysed using the intraclass correlation coeffi-
cient (ICC) (Shrout and Fleiss, 1979; Zlobec et al, 2006a). The ICC
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sis defined as the ratio of the between-subject variance over the
between-subjectþwithin subject variances and has previously
been used to assess agreement of IHC scores (Kirkegaard et al,
2006).
Selecting the cutoff scores for EGFR ‘positivity’ The selection of
cutoff scores for EGFR expression in both Study group 1 and 2A
were based on ROC curve analysis (Zlobec et al, 2006b). At each
score, the sensitivity and specificity for the outcome being studied
were plotted thus generating a ROC curve. The score located
closest to the point with both maximum sensitivity and specificity,
that is, the point (0.0, 1.0) on the curve, was selected as the cutoff
score leading to the greatest number of tumours which were
correctly classified as having or not having the outcome. To use
ROC curve analysis, the clinical and tumour characteristics must
be binary and were therefore dichotomized. For Study group 1 two
analyses were performed, the first to predict complete pathological
response (complete response vs partial or no response) and any
response (complete or partial response vs no response). For Study
group 2, T stage was dichotomized as early (T1þT2) or late
(T3þT4), N stage as N0 (no lymph node involvement) or 4N0
(any lymph node involvement), tumour grade as low (G1þG2) or
high (G3), vascular invasion as absent or present and survival as
death due to CRC or other (censored, alive or death from other
causes).
Reproducibility of ROC curve analysis To determine whether
ROC curve analysis was a reproducible method for selecting the
cutoff scores for EGFR, ROC curves were generated for each
independent pathologist and clinicopathological feature. In addi-
tion, 100-bootstrapped replications were performed to resample
the data and determine the reliability of the cutoff scores obtained
by each scorer. With bootstrapping, 100 resamples of equal size are
created and ROC curve analysis is performed for each subgroup.
Finally, the cutoff scores from each pathologist were averaged and
subsequently used to determine the association of EGFR over-
expression and the clinicopathological features on Study Group 2B.
The most frequently obtained cutoff score over the 100 resamples
the area under the ROC curve (AUC) and 95% CI were acquired
for each analysis. Area under the ROC curves summarise the
discriminatory power of EGFR for the outcome with values of 0.5
indicating low power and those closer to 1.0 higher power.
Association with clinicopathological features at the respective
cutoffs To determine the association of EGFR expression and
tumour response, logistic regression analysis was performed. The
odds ratio (OR) and 95% CI were obtained. The w
2 test was used to
evaluate EGFR expression with T stage, N stage, tumour grade and
vascular invasion. Survival analysis was carried out using the
Kaplan–Meier method and log-rank test. Cox proportional
hazards regression was used in multivariate survival analysis to
identify the prognostic value of EGFR independently of T stage, N
stage, tumour grade, vascular invasion and age. All analyses were
carried out using SAS (The SAS Institute, Cary, NC, USA). Receiver
operating characteristic curves were plotted using SPSS.
RESULTS
Tumour characteristics
Study Group 1 Twenty-seven tumours (32.9%) were completely
responsive to preoperative HDREB whereas 29 (35.4%) were non-
responsive and 30 (36.6%) were partially responsive to therapy.
Fifteen tumours (18.3%) showed no immunoreactivity (0%
staining) for EGFR whereas 67 (81.7%) displayed either membra-
nous or cytoplasmic positivity (Figure 1A and B). More than 90%
of patients were staged as cT3.
Study Group 2 EGFR immunoreactivity was evaluated in 1032
MMR-proficient CRCs. One hundred and sixty-five cases were not
assessed owing to the absence of tissue or tumour. Absence of
staining was found in 367 (35.6%) cases whereas membranous and/
or cytoplasmic staining was described in 64.4% (Figure 1C and D).
A
CD
B
Figure 1 Predominantly membranous (A) and cytoplasmic (B) EGFR expression in rectal adenocarcinoma ( 40). Membranous (C) and cytoplasmic
(D) EGFR staining in TMA punches of moderately differentiated MMR-proficient CRCs ( 40).
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sInter-observer agreement The ICCs obtained by analysing the
rectal tumour biopsies and TMA CRC punches were 0.71 and 0.86,
respectively.
ROC curve analysis The cutoff values for EGFR positivity or
overexpression were determined by ROC curve analysis. For the
three pathologists, a cutoff score was obtained (Table 1) for each
clinicopathological feature. Values were highly consistent between
pathologists. The average EGFR cutoff scores were obtained and
included 18% for predicting complete response, 15% for predicting
complete or partial response, 85% for T stage, and 10-year
survival, 75% for N stage, 82% for tumour grade and 80% for
vascular invasion. The ROC curves for each outcome are shown in
Figure 2.
Association of EGFR and clinicopathological features
(Table 2) Positive EGFR expression (418% tumour cell staining)
was significantly associated with complete pathological response
to preoperative HDREB (P-value o0.001; OR (95% CI)¼7.12 (2.3–
21.7)). Complete or partial tumour response was more frequently
associated with positive EGFR expression (415% tumour cell
staining) (P-value¼0.008; OR (95% CI)¼3.59 (1.37–9.43)).
Overexpression of EGFR (485% tumour cell staining) was more
frequently found in tumours with late T stage, although this
difference was only marginally significant (P¼0.069). No associa-
tion between EGFR overexpression and N stage (P-value¼0.792)
or vascular invasion (P¼0.753) was found. A marginally
significant difference in tumour grade with EGFR overexpression
was observed (P¼0.051).
Tumours with o85% EGFR staining had a significantly better
survival time (87.0 months (69.0–103.0)) (Po0.001) compared to
tumours overexpressing the protein (35.0 months (23.0–58.0))
(Figure 3). In a multivariate survival analysis adjusting for T stage,
N stage, tumour grade, vascular invasion and age, EGFR over-
expression was independently associated with worse survival time
(Po0.001) (HR (95% CI)¼1.93 (1.44–2.57)).
DISCUSSION
The predictive and prognostic value of EGFR in CRC varies
significantly in the literature. Several reasons have been suggested
for this discrepancy such as non-comparable study populations
(Spano et al, 2005a), variability in protocols, fixation and
antibodies (Atkins et al, 2004) and the lack of a uniform scoring
system (Penault-Llorca et al, 2005; Italiano, 2006; Walker, 2006).
The aim of this study was to determine the predictive and
prognostic value of EGFR in CRC based on cutoff scores selected to
maximise the clinical utility of EGFR findings by IHC. EGFR
expression and tumour response to a novel preoperative radiation
protocol, namely HDREB, was evaluated on whole tumour biopsy
specimens. In addition, 1197 CRCs from TMA punches were
randomised into two subgroups, the first used to select the cutoff
scores for EGFR overexpression, the second to analyse EGFR
overexpression and its association with tumour progression and
survival. The TMA approach is an accepted tool of investigation, in
particular with large sample sizes (Moch et al, 1999; Barlund et al,
2000; Nocito et al, 2001; Simon et al, 2001; Torhorst et al, 2001;
Sauter et al, 2003; Goethals et al, 2006).
The evaluation of immunoreactivity was carried out semiquan-
titatively by scoring the percentage of positive tumour cells in
both rectal tumour biopsy specimens and TMA punches. We have
previously shown that this scoring method leads to a more
complete assessment of the prognostic value of several tumour
markers in CRC when compared to an evaluation system based on
arbitrarily determined ‘positive’ or ‘negative’ scores (Lugli et al,
2006a–d). We have also shown that this scoring method is
reproducible among pathologists in rectal cancer using the ICC
which has recently been proposed as a method for determining
inter-observer variation of semicontinuous immunohistochemical
scores (Kirkegaard et al, 2006; Zlobec et al, 2006a). An ICC greater
than 0.7 should be regarded as the acceptable minimum standard
for declaring reliability (Kirkegaard et al, 2006). In this study, we
again validate this scoring method for EGFR among three
independent pathologists in rectal cancer biopsies (ICC¼0.71)
and TMA punches of CRC (ICC¼0.86).
ROC curves are commonly used in clinical oncology to
determine the threshold value above which a test result should
be considered positive for some outcome (Hanley, 1989;
Al-Homoud et al, 2004; Carpelan-Holmstrom et al, 2004; Chen
et al, 2005; Reid et al, 2005; Lind et al, 2006; Linke et al, 2006;
Punglia et al, 2006). We applied the same principle in this study to
determine the cutoff scores above which EGFR should be
considered overexpressed (Zlobec et al, 2006b). The reproduci-
bility of this method was validated by generating ROC curves for
each of the three pathologist’s scores in addition to resampling of
Table 1 Most frequently obtained cutoff score (mode), and area under the ROC curve (AUC (95% CI)) for each pathologist and clinicopathological
feature
Pathologist
Average
ROC features No. 1 No. 2 No. 3 cutoff scores
Predicting CR Cutoff score 10% 25% 20% 18%
AUC (95% CI) 0.63 (0.51–0.75) 0.654 (0.53–0.78) 0.70 (0.59–0.82)
Predicting CR or PR Cutoff score 10% 15% 20% 15%
AUC (95% CI) 0.571 (0.43–0.71) 0.652 (0.51–0.79) 0.60 (0.46–0.75)
T stage Cutoff score 90% 85% 80% 85%
AUC (95% CI) 0.594 (0.48–0.71) 0.579 (0.45–0.70) 0.533 (0.47–0.60)
N stage Cutoff score 80% 75% 70% 75%
AUC (95% CI) 0.536 (0.45–0.62) 0.552 (0.47–0.64) 0.505 (0.45–0.55)
Tumour grade Cut-off score 90% 85% 60% 82%
AUC (95% CI) 0.587 (0.41–0.77) 0.574 (0.41–0.74) 0.513 (0.43–0.60)
Vascular invasion Cutoff score 90% 75% 80% 80%
AUC (95% CI) 0.548 (0.45–0.64) 0.61 (0.52–0.70) 0.515 (0.46–0.57)
10-year survival Cutoff score 85% 90% 80% 85%
AUC (95% CI) 0.523 (0.44–0.61) 0.536 (0.45–0.62) 0.501 (0.44–0.56)
AUC¼area under ROC curve; CR¼complete response, PR¼partial response; ROC¼receiver operating characteristic.
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sthe data. The results of this study demonstrate that the selected
cutoff scores for each clinicopathological feature were highly
consistent among pathologists.
To obtain the best estimate of the EGFR expression in each
tumour, the three cutoff scores from each pathologist were
averaged. The cutoff score varied with the end point under
investigation. EGFR was considered to be overexpressed when
more than 15% of cells were stained when evaluating rectal tumour
response to HDREB but was significantly greater when analysing
features related to tumour progression and survival (X75%
staining). This difference in cutoff scores may be due to the
selection of patients into each Study Group. The rectal cancer
patients in Study Group 1 had predominantly cT3 tumours
whereas those in Study Group 2 were unselected and included
tumours of all T stages. The distribution of EGFR scores in both
study groups varied considerably with those in Study group 1
ranging from 0 to 90% with only 5% of tumours expressing EGFR
in more than 80% of tumour cells.
The findings of this study underline the fact that the selection of
cutoff scores for positivity should be performed for the specific
end point under investigation. The cutoff score of 15% is therefore
specific for predicting complete response in patients undergoing
treatment with preoperative HDREB and may not be generalisable
to other forms of radiotherapy for which cutoff scores can be
established.
When investigating outcomes, such as response to anti-EGFR
therapy, it may be more beneficial to choose a cutoff score leading
to high sensitivity rather than specificity for tumour response to
select the greatest number of potentially responsive candidates for
treatment. In this study, the cutoff score was selected such that
it maximised the number of correctly classified tumours with
and without the end point being under evaluation (maximum
sensitivity with minimal loss of specificity).
At the selected cutoff scores, EGFR overexpression was
significantly associated with improved response to preoperative
HDREB. Complete pathological response was more than seven
times more likely to occur in tumours overexpressing EGFR
whereas complete or partial response was found to occur nearly
four times more often in these cases. These results are in line with
reports in head and neck squamous cell carcinoma investigating
the predictive value of EGFR using a high-dose rate approach
(Eriksen et al, 2004; Bentzen et al, 2005).
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Figure 2 ROC curves plotted for each clinicopathological feature using scores from one of the three pathologists (A) complete tumour response, (B)
complete or partial tumour response, (C) T stage, (D) N stage, (E) tumour grade, (F) vascular invasion and (G) 10-year survival. Arrows indicate the closest
point on the ROC curves to the point (0.0, 1.0), which correspond to the selected cut-off score.
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ciated with N stage or vascular invasion and led to marginally
significant associations with T stage and tumour grade. These
results are supported by similar findings by other groups that have
shown no relationship between EGFR overexpression and disease
evolution (Yasui et al, 1988; Moorghen et al, 1990; Koenders et al,
1992; Saeki et al, 1995; Goldstein and Armin, 2001; Yarden and
Sliwkowski, 2001; McKay et al, 2002; Spano et al, 2005b). However,
patients with EGFR overexpressing tumours (X85% tumour cell
staining) demonstrated a significantly worse prognosis (35.0
months (23.0–58.0)) than those with no overexpression (87.0
months (69.0–103.0)). Previous reports also support these findings
(Gross et al, 1991; Mayer et al, 1993; Khorana et al, 2003; Resnick
et al, 2004; Galizia et al, 2006). Moreover, EGFR in this study was
found to predict worse survival in a multivariate analysis
independently of known adverse prognostic factors including T
stage, N stage and vascular invasion. These results indicate that
EGFR expression evaluated at a cutoff of 85% could be used as a
prognostic marker in addition to pathological staging.
In conclusion, EGFR is a predictive marker of response to
preoperative HDREB in rectal cancers and an independent adverse
prognostic factor in MMR-proficient CRC. The combination of
semiquantitative evaluation of EGFR expression and ROC curve
analysis which was validated in this study proves to be a
reproducible method for selecting the cutoff scores for EGFR
overexpression in CRC.
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